Financial framing remained anchored on the same runway and 2026 cash operating expense guidance, while Q1 2026 highlighted a "30% year-over-year reduction" in cash operating expenses and quarter-end ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...

Recursion can feel like magic until you understand its simple rules: a base case to stop, and a recursive call to repeat. By breaking problems into smaller versions of themselves, recursion makes ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...